Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and PD of Milvexian in Healthy Adults
NCT04223349Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of milvexian in thromboembolism (10 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Analyte Concentration, Time to Reach Maximum Observed Analyte Concentration and 4 more. Started Jan 2020; status: completed.
02
Drugs
milvexian
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT04223349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04223349.